Jones Financial Companies
TPST icon

Jones Financial Companies’s Tempest Therapeutics TPST Stock Holding History

Jones Financial Companies’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258 Hold
239
– – ﹤0.01% 4836
2026
Q1 		$413 Hold
239
– – ﹤0.01% 4520
2025
Q4 		$686 Buy
+239
New +$1.69K ﹤0.01% 4100

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jones Financial Companies's TPST Position: Q2 2026 in Review

Jones Financial Companies held its Tempest Therapeutics (TPST) position steady in Q2 2026 at 239 shares worth $258. The position accounts for ﹤0.01% of the portfolio, ranked #4836.

Jones Financial Companies first reported a position in TPST in Q4 2025 and has held it in 3 quarters since. The position peaked at $686 in Q4 2025. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

  • Jones Financial Companies held 239 shares of Tempest Therapeutics worth $258 as of Q2 2026.
  • Jones Financial Companies left its Tempest Therapeutics share count unchanged in Q2 2026.
  • Tempest Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4836 holding.
  • Jones Financial Companies first reported a position in Tempest Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Jones Financial Companies's Tempest Therapeutics position peaked at $686 in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.